May 10: The Week in Cancer News
People may be able to wait longer between colonoscopies, and a trial evaluates a less invasive option for treating prostate cancer.
Progress Against Cancer
People may be able to wait longer between colonoscopies, and a trial evaluates a less invasive option for treating prostate cancer.
Updated recommendation lowers age for breast cancer screening, and laboratory tests will undergo greater FDA oversight.
Tisotumab vedotin-tftv is approved to treat certain recurrent or metastatic cervical cancers. The U.S. Food and Drug Administration (FDA) has approved tisotumab vedotin-tftv (Tivdak) for patients with recurrent or metastatic cervical cancer whose disease...
Scientists thought pancreatic cancer wouldn’t respond to immunotherapy. Now research has found vaccines can trigger the immune system to fight the disease.
Supplemental breast screenings are not covered by Medicare, and researchers develop a treatment option for a form of eye cancer.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
The FDA approved the BRAF inhibitor tovorafenib for pediatric patients with certain Genetic alterations. The U.S. Food and Drug Administration (FDA) has approved tovorafenib (Ojemda) for the treatment of pediatric patients aged 6 months...
The FDA has approved lutetium Lu 177 dotatate for children 12 years or older with some gastroenteropancreatic neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 dotatate (Lutathera) for...
The FDA has approved nogapendekin alfa inbakicept-pmln, which stimulates immune cells to fight bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with Bacillus Calmette-Guérin (BCG),...
A urine test may help grade prostate cancers without biopsies, and states look for savings and better health in palliative care.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More